Health care pharmaceutical companies by P/E ratio
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Edgewise Therapeutics has the lowest figure of the 33 health care pharmaceutical companies ranked by P/E ratio, at 4.9, followed by Alnylam Pharmaceuticals (7.5) and Novo Nordisk (9.8). Figures as of 20 Nov 2026, 05:37 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 33
- Lowest
- Edgewise Therapeutics4.9
- Median
- 39.3
- Combined market value
- ZAR 86.99T
- Countries
- 10
- Not ranked
- 28no P/E ratio on file
Market values as of .
All countries▾
Health Care▾
Pharmaceuticals▾
| # | Company | P/E ↑ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Edgewise TherapeuticsEWTX · Health Care | 4.9 | ZAR 79B | ZAR 721.75 | 0.48% down | 86% up | ||
| 2 | Alnylam PharmaceuticalsALNY · Health Care | 7.5 | ZAR 347.1B | ZAR 2,591.44 | 1.06% down | 66% down | ||
| 3 | Novo NordiskNVO · Health Care | 9.8 | ZAR 3T | ZAR 681.43 | 1.42% down | 17% down | ||
| 4 | GrifolsGRFS · Health Care | 9.9 | ZAR 97.8B | ZAR 143.75 | 3.19% down | 0% up | ||
| 5 | Bristol-Myers SquibbBMY · Health Care | 13.2 | ZAR 2.09T | ZAR 1,022.76 | 2.05% down | 30% up | ||
| 6 | ZoetisZTS · Health Care | 13.7 | ZAR 575.5B | ZAR 1,416.34 | 5.59% down | 26% down | ||
| 7 | GSKGSK · Health Care | 16.7 | ZAR 1.68T | ZAR 838.34 | 1.56% down | 5% up | ||
| 8 | Ascendis PharmaASND · Health Care | 16.8 | ZAR 294.3B | ZAR 4,487.25 | 5.32% down | 29% up | ||
| 9 | Regeneron PharmaceuticalsREGN · Health Care | 20.4 | ZAR 1.67T | ZAR 16,187.14 | 2.35% down | 28% up | ||
| 10 | United TherapeuticsUTHR · Health Care | 21.1 | ZAR 417.4B | ZAR 9,801.62 | 3.16% down | 22% up | ||
| 11 | SanofiSNY · Health Care | 22.9 | ZAR 1.94T | ZAR 807.48 | 2.25% down | 4% down | ||
| 12 | AstraZenecaAZN · Health Care | 24.8 | ZAR 4.77T | ZAR 3,075.12 | 1.87% down | 1% up | ||
| 13 | Protagonist TherapeuticsPTGX · Health Care | 26.9 | ZAR 141.9B | ZAR 2,174.20 | 2.47% down | 51% up | ||
| 14 | NovartisNVS · Health Care | 29.6 | ZAR 5.01T | ZAR 2,651.05 | 2.57% down | 25% up | ||
| 15 | Vertex PharmaceuticalsVRTX · Health Care | 33.5 | ZAR 2.31T | ZAR 9,127.73 | 2.94% down | 27% up | ||
| 16 | Abbott LaboratoriesABT · Health Care | 38.8 | ZAR 3.15T | ZAR 1,820.95 | 0.58% down | 16% down | ||
| 17 | PfizerPFE · Health Care | 39.3 | ZAR 2.75T | ZAR 482.81 | 1.85% down | 15% up | ||
| 18 | Johnson & JohnsonJNJ · Health Care | 40.5 | ZAR 11.27T | ZAR 4,683.25 | 2.04% down | 34% up | ||
| 19 | Dr. Reddy's LaboratoriesRDY · Health Care | 41.2 | ZAR 216.7B | ZAR 259.99 | 1.00% down | 8% up | ||
| 20 | Eli LillyLLY · Health Care | 43.9 | ZAR 21.1T | ZAR 23,686.58 | 2.29% down | 33% up | ||
| 21 | GenmabGMAB · Health Care | 43.9 | ZAR 555.1B | ZAR 900.22 | 0.75% up | 70% up | ||
| 22 | Royalty PharmaRPRX · Health Care | 44.3 | ZAR 682.6B | ZAR 1,187.20 | 1.38% down | 79% up | ||
| 23 | AbbVieABBV · Health Care | 48.7 | ZAR 8.79T | ZAR 4,970.76 | 0.86% down | 25% up | ||
| 24 | Corcept TherapeuticsCORT · Health Care | 51.2 | ZAR 124.7B | ZAR 1,139.17 | 4.15% down | 10% down | ||
| 25 | BeOne MedicinesONC · Health Care | 51.8 | ZAR 800.4B | ZAR 7,007.17 | 0.97% down | 16% up | ||
| 26 | Amneal PharmaceuticalsAMRX · Health Care | 53.5 | ZAR 130.7B | ZAR 374.99 | 2.24% down | 90% up | ||
| 27 | Jazz PharmaceuticalsJAZZ · Health Care | 70.0 | ZAR 266.1B | ZAR 4,145.22 | 4.57% down | 41% up | ||
| 28 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | 72.0 | ZAR 128.8B | ZAR 1,639.77 | 1.59% down | 129% up | ||
| 29 | Teva Pharmaceutical IndustriesTEVA · Health Care | 89.6 | ZAR 788.4B | ZAR 675.65 | 8.74% down | 74% up | ||
| 30 | TG TherapeuticsTGTX · Health Care | 98.3 | ZAR 171.9B | ZAR 1,137.42 | 1.88% down | 117% up | ||
| 31 | Ligand PharmaceuticalsLGND · Health Care | 115 | ZAR 100.6B | ZAR 5,030.37 | 3.94% down | 50% up | ||
| 32 | Merck & CoMRK · Health Care | 134 | ZAR 5.74T | ZAR 2,328.30 | 3.61% down | 45% up | ||
| 33 | Takeda PharmaceuticalTAK · Health Care | 306 | ZAR 1.2T | ZAR 375.34 | 0.66% up | 51% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 17.5311 ZAR). 28 companies have no P/E ratio on file and are not ranked here.
Questions and answers
Which health care pharmaceutical companies have the lowest P/E ratio?
Edgewise Therapeutics (4.9), Alnylam Pharmaceuticals (7.5) and Novo Nordisk (9.8) have the lowest P/E ratio of the 33 health care pharmaceutical companies ranked here as of 20 Nov 2026, 05:37 UTC.
How many health care pharmaceutical companies are in this ranking?
33 are ranked by P/E ratio. 28 more have no P/E ratio on file and are left out rather than ranked at zero.
What are these health care pharmaceutical companies worth together?
The 33 health care pharmaceutical companies ranked by P/E ratio have a combined market value of ZAR 86.99T as of 20 Nov 2026, 05:37 UTC.
What does ranking by P/E ratio measure?
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- PEG ratio: P/E adjusted for growth, and its limits
The PEG ratio is a stock's P/E divided by its expected yearly earnings growth in percent. A P/E of 20 with 10% expected growth gives a PEG of 2; with 20% growth, a PEG of 1. A PEG near 1 is the traditional rough mark of a fair price, but the growth figure is a forecast and often wrong.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Health care pharmaceutical companies by P/E ratio”, data as of 20 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?sector=health-care&by=pe-ratio
Underlying data: Yahoo Finance; SEC EDGAR.